Purpose: Sodium-glucose cotransporter-2 inhibitors promote cardiac reverse remodeling in heart failure (HF), yet data integrating two-dimensional and three-dimensional echocardiography (2DE and 3DE, respectively) in optimally treated HFrEF populations are limited. This study aimed to evaluate heart chambers size and function by 2D/3DE after dapagliflozin initiation, and to explore whether baseline estimated glomerular filtration rate (eGFR) or myocardial fibrosis on cardiac magnetic resonance (CMR) influence reverse remodeling. Methods: Seventy-five patients with LVEF ≤ 40% on guideline-directed therapy were prospectively enrolled. Echocardiographic and clinical data were collected at baseline and 6-month follow-up (6MFU) after introduction of dapagliflozin 10 mg daily. Sub- analyses were performed according to eGFR ( < 45 vs. ≥ 45 mL/min/1.73 m2 ) and extent of late gadolinium enhancement (LGE) on CMR. Results: After 6MFU, left ventricular (LV) end-diastolic and end-systolic volumes reduced, and LVEF increased as assessed by both 2DE (respectively: 88[72–122] vs. 92[79–122]mL/m2 , 58[42–80] vs. 57[48–88]mL/m2 , 36.6 ± 8.8 vs. 34.5 ± 7.7%; p < 0.001) and 3DE (respectively: 100[79–140] vs. 108[90–136]mL/m2 , 64[46–82] vs. 69[55–93]mL/m2 , 37.4 ± 8.7 vs. 34.4 ± 7.9%; p < 0.001). No significant association between eGFR and the magnitude of LV reverse remodeling was detected, while CMR analyses suggested a possible inverse correlation between LGE burden and improvement in 2D LVEF. LV diastolic function improved (grade ≥ 2 diastolic dysfunction: 4.7% vs. 18.7%; p = 0.015), along with systolic pulmonary artery pressure (25[23–29] vs. 27[24–29]mmHg; p = 0.037). Conclusion: In optimally treated HFrEF patients, LV size and systolic and diastolic function significantly improved during the 6MFU following dapagliflozin initiation. No significant differences in the magnitude of LV reverse remodeling were detected according to eGFR or LGE burden.

DAPAgliflozin‐Related Cardiac REverse Remodeling by 2D and 3D Echocardiography in OptiMally Treated HFrEF Patients: The DAPA‐REM Study / N. Amelotti, V.M.. - In: ECHOCARDIOGRAPHY. - ISSN 0742-2822. - 43:10(2026 Oct 25), pp. e70654.1-e70654.12. [10.1111/echo.70654]

DAPAgliflozin‐Related Cardiac REverse Remodeling by 2D and 3D Echocardiography in OptiMally Treated HFrEF Patients: The DAPA‐REM Study

N. Amelotti
Co-primo
;
V. Mantegazza
Co-primo
;
E. Salvioni;M. Mapelli;A. Baggiano;P. Agostoni
Penultimo
;
G. Pontone
Ultimo
2026

Abstract

Purpose: Sodium-glucose cotransporter-2 inhibitors promote cardiac reverse remodeling in heart failure (HF), yet data integrating two-dimensional and three-dimensional echocardiography (2DE and 3DE, respectively) in optimally treated HFrEF populations are limited. This study aimed to evaluate heart chambers size and function by 2D/3DE after dapagliflozin initiation, and to explore whether baseline estimated glomerular filtration rate (eGFR) or myocardial fibrosis on cardiac magnetic resonance (CMR) influence reverse remodeling. Methods: Seventy-five patients with LVEF ≤ 40% on guideline-directed therapy were prospectively enrolled. Echocardiographic and clinical data were collected at baseline and 6-month follow-up (6MFU) after introduction of dapagliflozin 10 mg daily. Sub- analyses were performed according to eGFR ( < 45 vs. ≥ 45 mL/min/1.73 m2 ) and extent of late gadolinium enhancement (LGE) on CMR. Results: After 6MFU, left ventricular (LV) end-diastolic and end-systolic volumes reduced, and LVEF increased as assessed by both 2DE (respectively: 88[72–122] vs. 92[79–122]mL/m2 , 58[42–80] vs. 57[48–88]mL/m2 , 36.6 ± 8.8 vs. 34.5 ± 7.7%; p < 0.001) and 3DE (respectively: 100[79–140] vs. 108[90–136]mL/m2 , 64[46–82] vs. 69[55–93]mL/m2 , 37.4 ± 8.7 vs. 34.4 ± 7.9%; p < 0.001). No significant association between eGFR and the magnitude of LV reverse remodeling was detected, while CMR analyses suggested a possible inverse correlation between LGE burden and improvement in 2D LVEF. LV diastolic function improved (grade ≥ 2 diastolic dysfunction: 4.7% vs. 18.7%; p = 0.015), along with systolic pulmonary artery pressure (25[23–29] vs. 27[24–29]mmHg; p = 0.037). Conclusion: In optimally treated HFrEF patients, LV size and systolic and diastolic function significantly improved during the 6MFU following dapagliflozin initiation. No significant differences in the magnitude of LV reverse remodeling were detected according to eGFR or LGE burden.
HFrEF; SGLT2‐i; dapagliflozin; heart failure; reverse remodeling
Settore MEDS-07/B - Malattie dell'apparato cardiovascolare
25-ott-2026
Article (author)
File in questo prodotto:
File Dimensione Formato  
Echocardiography - 2026 - Amelotti - DAPAgliflozin‐Related Cardiac REverse Remodeling by 2D and 3D Echocardiography in.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Licenza: Nessuna licenza
Dimensione 1.59 MB
Formato Adobe PDF
1.59 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1275840
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
  • OpenAlex ND
social impact